Coronary Drug Eluting Products

Drug Eluting Therapies

Coronary Drug Eluting Products

Are you using the right DES or DCB for every coronary lesion?

With a Modern PCI approach to See, Prep and Treat, you can choose the best treatment option for every patient depending on their lesion and disease burden.

Choose a gold-standard treatment option for every lesion.

Agent™ Drug Coated Balloon

AGENT™ Drug Coated Balloon

Designed to make reliable drug transfer more deliverable for:

  • In Stent Restenosis (ISR)
  • Small Vessel Disease
  • De Novo Lesions
  • Long Diffuse Disease
Get to know AGENT DCB
Agent™ Drug Coated Balloon

SYNERGY MEGATRON™ Drug Eluting Stent

Purpose-built coronary stent specifically for 

  • Large Proximal Vessels, Left Main Artery, Right Coronary Artery (RCA), Ostial
  • Large Calcified Vessels
  • Bifurcations
Explore SYNERGY MEGATRON DES
Agent™ Drug Coated Balloon

SYNERGY™ XD Drug Eluting Stent

Intentionally designed PCI DES for: 

  • Deliverability in complex lesions 
  • Short DAPT in HBR patients
Explore SYNERGY XD DES

AGENT DCB and SYNERGY DES are clinically proven

SYNERGY DES platform clinical evidence

SYNERGY DES platform clinical evidence

The SYNERGY Bioabsorbable Polymer Stent Platform has been studied in over 35,000 patients across various patient and lesion complexities.

Explore clinical data, meta-analyses and real-world evidence supporting the SYNERGY DES Platform
AGENT IDE Trial explained

AGENT IDE Trial explained

The AGENT IDE Clinical Trial showed that AGENT DCB is superior to conventional balloon angioplasty in reducing target lesion failure for the treatment of coronary in-stent restenosis (ISR).1

Get the full details on the trail that got AGENT FDA approved.

Benefit from a Modern PCI approach to coronary lesions

When you See, Prep, and Treat a vessel with the best-in-class Modern PCI portfolio, you’re committing to durable and predictable outcomes that redefine the standard of care.

Discover the full Modern PCI portfolio

References:

1. Yeh, R, et all, Rationale and design of a randomized study comparing the agent drug coated balloon to the plain old balloon angioplasty in patients with In-Stent Restenosis,​ American Heart Journal 2021.

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.